Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin

References

• Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. Journal of the American Medical Association 1996; 275: 128–133
   PubMed Web of Science ®Google Scholar
• Fukuda T, Onishi S, Fukuen S, Ikenaga Y, Ohno M, Hoshino K, Matsumoto K, Maihara A, Momiyama K, Ito T, et al. CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers. Pharmacogenomics Journal 2004; 4: 34–39
   PubMedGoogle Scholar
• Huang W, Lin YS, McConn DJ, II, Calamia JC, Totah RA, Isoherranen N, Glodowski M, Thummel KE. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metabolism and Disposition 2004; 32: 1434–1445
   PubMed Web of Science ®Google Scholar
• Jacobsen W, Kuhn B, Soldner A, Kirchner G, Sewing KF, Kollman PA, Benet LZ, Christians U. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metabolism and Disposition 2000; 28: 1369–1378
   PubMed Web of Science ®Google Scholar
• Josephson F, Allqvist A, Janabi M, Sayi J, Aklillu E, Jande M, Mahindi M, Burhenne J, Bottiger Y, Gustafsson LL, et al. CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir. Clinical Pharmacology and Therapy 2007; 81: 708–712
   PubMed Web of Science ®Google Scholar
• Kantola T, Kivisto KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clinical Pharmacology and Therapy 1998; 64: 58–65
   PubMed Web of Science ®Google Scholar
• Kearney AS, Crawford LF, Mehta SC, Radebaugh GW. The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981. Pharmacology Research 1993; 10: 1461–1465
   PubMed Web of Science ®Google Scholar
• Kim KA, Park PW, Lee OJ, Choi SH, Min BH, Shin KH, Chun BG, Shin JG, Park JY. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. Clinical Pharmacology and Therapy 2006; 80: 646–656
   PubMed Web of Science ®Google Scholar
• Kim KA, Park PW, Lee OJ, Kang DK, Park JY. Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. Journal of Clinical Pharmacology 2007; 47: 87–93
   PubMed Web of Science ®Google Scholar
• Kivisto KT, Niemi M, Schaeffeler E, Pitkala K, Tilvis R, Fromm MF, Schwab M, Eichelbaum M, Strandberg T. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 2004; 14: 523–525
   PubMedGoogle Scholar
• Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, Thummel KE. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Molecular Pharmacology 2002; 62: 162–172
   PubMed Web of Science ®Google Scholar
• Lins RL, Matthys KE, Verpooten GA, Peeters PC, Dratwa M, Stolear JC, Lameire NH. Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. Nephrology and Dial Transplant 2003; 18: 967–976
   PubMed Web of Science ®Google Scholar
• Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, Jones PH, Haber HE, Black DM. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arteriosclerosis and Thrombo-Vascular Biology 1995; 15: 678–682
   PubMed Web of Science ®Google Scholar
• Park JY, Kim KA, Park PW, Lee OJ, Kang DK, Shon JH, Liu KH, Shin JG. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects. Clinical Pharmacology and Therapy 2006; 79: 590–599
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Gorham LM, Ma B, Liu L, Yu X, Zhao JJ, Slaughter DE, Arison BH, Vyas KP. In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metabolism and Disposition 1997; 25: 1191–1199
   PubMed Web of Science ®Google Scholar
• Raghubir N. Concurrent use of clopidogrel (Plavix) and atorvastatin (Lipitor) is contraindicated. South African Medical Journal 2006; 96: 474
   PubMed Web of Science ®Google Scholar
• Rodrigues AD. Integrated cytochrome P450 reaction phenotyping: Attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochemistry and Pharmacology 1999; 57: 465–480
   PubMed Web of Science ®Google Scholar
• Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update. Fundamentals in Clinical Pharmacology 2005; 19: 117–125
   PubMed Web of Science ®Google Scholar
• Schrag ML, Wienkers LC. Triazolam substrate inhibition: evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site. Drug Metabolism and Disposition 2001; 29: 70–75
   PubMed Web of Science ®Google Scholar
• Schuetz EG, Relling MV, Kishi S, Yang W, Das S, Chen P, Cook EH, Rosner GL, Pui CH, Blanco JG, et al. PharmGKB update: II. CYP3A5, cytochrome P450, family 3, subfamily A, polypeptide 5. Pharmacology Reviews 2004; 56: 159
   PubMedGoogle Scholar
• Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapy 1994; 270: 414–423
   PubMed Web of Science ®Google Scholar
• Warrington JS, Shader RI, Von Moltke LL, Greenblatt DJ. In vitro biotransformation of sildenafil (Viagra): Identification of human cytochromes and potential drug interactions. Drug Metabolism and Disposition 2000; 28: 392–397
   PubMed Web of Science ®Google Scholar
• Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, Vandenbranden M. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Molecular Pharmacology 1990; 38: 207–213
   PubMed Web of Science ®Google Scholar
• Yamaori S, Yamazaki H, Iwano S, Kiyotani K, Matsumura K, Honda G, Nakagawa K, Ishizaki T, Kamataki T. CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects. Drug Metabolism and Pharmacokinetics 2004; 19: 120–129
   PubMedGoogle Scholar
• Yu KS, Cho JY, Jang IJ, Hong KS, Chung JY, Kim JR, Lim HS, Oh DS, Yi SY, Liu KH, et al. Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Clinical Pharmacology and Therapy 2004; 76: 104–112
   PubMed Web of Science ®Google Scholar